न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - pemetrexed disodium hemipentahydrate 120.81mg equivalent to pemetrexed 100mg - powder for infusion - 100 mg - active: pemetrexed disodium hemipentahydrate 120.81mg equivalent to pemetrexed 100mg excipient: hydrochloric acid mannitol sodium hydroxide - pemetrexed, in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - pemetrexed disodium hemipentahydrate 604.05mg equivalent to pemetrexed 500mg - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.05mg equivalent to pemetrexed 500mg excipient: hydrochloric acid mannitol sodium hydroxide - pemetrexed, in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - pemetrexed disodium, quantity: 110.3 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - pemetrexed disodium, quantity: 110.3 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - pemetrexed disodium, quantity: 551.5 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - pemetrexed disodium, quantity: 551.5 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - pemetrexed disodium, quantity: 551.5 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

steriscience pty ltd - pemetrexed disodium, quantity: 110.3 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

steriscience pty ltd - pemetrexed disodium, quantity: 551.5 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - pemetrexed disodium, quantity: 110.3 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.